One Federal Agency Called It a Breakthrough. Another Wants It in Schedule I.

Two psychedelic policy decisions landed within twenty-four hours of each other in late September 2026, and they point in opposite directions.

On September 22, the Oregon Health Authority announced it would abandon a plan to double licensing fees across the state’s psilocybin services program. On September 23, the Drug Enforcement Administration published a proposed rule to place five tryptamine compounds into Schedule I — the most restrictive category in federal drug law, reserved for substances with “no currently accepted medical use.”

One of those five compounds is the active molecule in a drug candidate the Food and Drug Administration singled out for expedited review seven months ago.

That is not a contradiction anyone has to infer. It is two federal agencies, on the record, reaching opposite conclusions about the same chemical.

What Oregon actually did

The Oregon Health Authority (OHA) had proposed a substantial fee increase across its psilocybin program:

• Annual licensing fees for manufacturers and service centers: $10,000 → $20,000
• Annual fees for facilitators: $2,000 → $4,000
• First-time application fees: $500 → $1,000

On September 22, 2026, OHA said it would not file final rules from that rulemaking process and would not adopt the increases. The agency pointed to feedback from three places: the Oregon Psilocybin Advisory Board (OPAB) — the state’s own statutory advisory body — along with its rule advisory committees and the public comment period.

OHA has said it will open a separate rulemaking process in the coming weeks covering the program changes that were unrelated to fees, with a planned effective date of January 15, 2027.

Worth being precise about what this is and is not. It is not a change in what the program permits, who can participate, or how services are delivered. It is a cost-of-participation decision — and in a program where licensees have publicly described thin margins, the difference between a $10,000 and a $20,000 annual fee is a question of who can afford to stay licensed at all.

What the DEA proposed

The DEA’s proposed rule, published in the Federal Register on September 23, 2026 (document 2026-19400), would place five tryptamines into Schedule I:

• 4-OH-DiPT (4-hydroxy-N,N-diisopropyltryptamine)
• 5-MeO-AMT (5-methoxy-alpha-methyltryptamine)
• 5-MeO-MiPT (5-methoxy-N-methyl-N-isopropyltryptamine)
• 5-MeO-DET (5-methoxy-N,N-diethyltryptamine)
• DiPT (N,N-diisopropyltryptamine)

Comments and requests for a hearing are due October 23, 2026, under docket DEA-2026-1585 at regulations.gov.

Two pieces of context matter more than the list itself.

First, this is the second attempt. The DEA proposed scheduling these same five compounds in 2022 and withdrew the proposal after a strong public comment response, including from researchers and companies arguing the restrictions would encumber legitimate science.

Second, the current proposal follows an updated health review. The Department of Health and Human Services delivered its recommendation supporting Schedule I placement on April 2, 2026, and the DEA reported reaching the same conclusion in its own updated analysis in May.

Why is 4-OH-DiPT the compound that matters here?

4-OH-DiPT is not an obscure research chemical in this story. It is the active moiety of luvesilocin (formerly RE104), a prodrug developed by Reunion Neuroscience and studied for postpartum depression.

On February 23, 2026, the FDA granted luvesilocin Breakthrough Therapy Designation for postpartum depression, on the basis of its Phase 2 RECONNECT trial.

A correction worth making, because the shorthand is circulating: this was Breakthrough Therapy Designation, not Fast Track. They are different FDA programs with different criteria. Fast Track is the broader and easier designation to obtain. Breakthrough Therapy is the narrower one — it requires preliminary clinical evidence suggesting substantial improvement over available therapies on a clinically significant endpoint. Calling it “fast-tracked” understates what the FDA actually said.

So within a single federal government, in a single year: one agency concluded the preliminary clinical evidence was strong enough to warrant expedited development, and another proposed a finding that the same molecule has no currently accepted medical use.

Would Schedule I placement stop the research?

This is where the coverage tends to overshoot, so here is the careful version.

A proposed rule is not a final rule. Nothing is scheduled today. The comment period runs to October 23, a hearing can be requested, and the DEA withdrew this exact proposal once before.

Schedule I placement would not automatically end the luvesilocin program. Researchers can and do study Schedule I substances — psilocybin research proceeds under exactly that status. But it requires DEA registration, controlled storage, and compliance obligations that add cost, delay, and administrative burden at every site.

And there is precedent for the eventual resolution. When the FDA approves a drug product containing a controlled substance, that product is typically placed in a less restrictive schedule at approval — as happened with Epidiolex, a cannabidiol medication. Scheduling the underlying compound now creates friction for the development pathway; it does not, by itself, foreclose an approval later.

What it does mean, concretely, is that the research gets harder and more expensive during the years when the pivotal trials would be run.

The thread connecting both stories

The Oregon reversal and the 2022 DEA withdrawal have the same mechanism underneath them. In both cases, an agency proposed something, an advisory body and the public pushed back through the formal comment process, and the agency changed course.

That is worth noticing precisely because it is unglamorous. Oregon’s advisory board is a statutory body doing the thing statutory bodies exist to do. The DEA’s 2022 withdrawal followed an ordinary public comment docket. Neither required a lawsuit or a ballot measure.

It is not a guarantee. Agencies weigh comments; they are not bound by a headcount, and the DEA has returned with the same proposal and a fresh HHS recommendation behind it. But for anyone who follows this field and has wondered whether the formal process does anything at all, the record in both of these stories is that it has.

The docket is open until October 23, 2026.

What we are watching

• Whether a hearing is requested and granted on the DEA proposal, and what the comment volume looks like relative to 2022.
• Whether Reunion, researchers, or professional bodies file in the docket, and what arguments they make about the research-access burden.
• Oregon’s replacement rulemaking, and whether the fee question returns in another form — the underlying program funding pressure that prompted the proposal has not gone away.
• Whether luvesilocin enters Phase 3 as planned, and on what timeline.

We will report what the record shows, including if it cuts against the expectations above.

ShroomWire reports on mushroom, psychedelic, and brain-health research. We are not doctors, and nothing here is medical, dosing, or treatment advice. Luvesilocin is an investigational drug that is not approved by the FDA, and the compounds named in the DEA proposal are not approved medicines. Nothing in this article is a recommendation to use any substance. If you are struggling with your mental health, or with symptoms after childbirth, please talk to a qualified professional.

Sources

• ¶Oregon Health Authority, “OHA statement: Agency not moving forward with proposed fee increases for psilocybin licensees,” September 22, 2026.
• ¶Federal Register, “Schedules of Controlled Substances: Placement of 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT Into Schedule I,” proposed rule, document 2026-19400, published September 23, 2026. Docket DEA-2026-1585.
• ¶Reunion Neuroscience, “U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status,” February 23, 2026.

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.